No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The NY ESO 1 Targeted Immunotherapy market is a subset of the larger Oncology Drugs market. It is focused on the development of treatments that target the NY ESO 1 antigen, which is found in certain types of cancer. These treatments are designed to stimulate the body's immune system to recognize and attack cancer cells that express the antigen. This type of immunotherapy has been shown to be effective in treating certain types of cancer, such as ovarian cancer, and is being studied for its potential to treat other types of cancer.
The NY ESO 1 Targeted Immunotherapy market is highly competitive, with many companies developing treatments that target the antigen. Some of the major players in the market include Merck, Bristol-Myers Squibb, AstraZeneca, Pfizer, and Novartis. Other companies, such as Immunocore, are also developing treatments that target the NY ESO 1 antigen. Show Less Read more
